Bank of America Raises Hims and Hers Stock Price Target
Bank of America raised its price target on Hims & Hers (HIMS) to $32 from $30, citing the company's ability to prescribe Eli Lilly's weight-loss medications through the LillyDirect pharmacy system. This follows a previous price target increase in April, driven by the FDA's peptide announcement. The move reflects growing analyst interest in Hims & Hers amid developments in digital health.
Topics: analyst upgrade digital health pharmaceutical partnerships stock price target